Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301572 · ClinicalTrials.gov registry record
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 750
- Enrollment target
NCT02301572: Completed study, sponsored by Weill Medical College of Cornell University.
NCT02301572 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 750 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02301572 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
Chart review.
Primary Outcome
Disability outcomes will be determined based on EDDS at last visit. EDSS at last follow up will be compared to EDSS at start of respective therapies and grouped into 3 categories: EDSS improved, EDSS no change and EDSS worsened. Multivariate logistic regression will be used to test individual variables that could potentially influence the outcome, including treatment, age at onset, gender and race.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-08 |
What the finished NCT02301572 record still lists
NCT02301572 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02301572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02301572 about?
NCT02301572 is a clinical study titled "Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course". Chart review.
What is the current status of trial NCT02301572?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2014-08. Estimated completion is 2016-08.
Who is sponsoring clinical trial NCT02301572?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia